文献速递脑血管病外科神经重症

低剂量与治疗范围静脉普通肝素预防在动脉瘤闭塞后重症动脉瘤性蛛网膜下腔出血患者治疗中的比较

Low-Dose versus Therapeutic Range Intravenous Unfractionated Heparin Prophylaxis in the Treatment of Patients with Severe Aneurysmal Subarachnoid Hemorrhage After Aneurysm Occlusion.
PubMed 文献 · World Neurosurg · 2018-06-27

回顾性分析410例重症动脉瘤性蛛网膜下腔出血(Fisher 3-4级)且完全闭塞动脉瘤的患者,比较低剂量(aPTT<40秒)与治疗范围(aPTT 50-60秒)静脉普通肝素预防的效果。低剂量组与治疗范围组的静脉血栓栓塞事件发生率无显著差异,但治疗范围组初始SAH相关脑出血增加显著更频繁(18.8% vs 3.4%,P=0.007)。结论认为低剂量普通肝素预防静脉血栓栓塞与治疗剂量同样有效且出血风险更低。

要点

  • 低剂量普通肝素组静脉血栓栓塞发生率为5.4%,治疗剂量组为6.3%,两组静脉血栓栓塞事件发生率和严重程度无显著差异。
  • 治疗剂量组初始SAH相关脑出血增加显著更频繁(18.8% vs 3.4%,P=0.007)。
  • 肝素诱导的血小板减少症是静脉血栓栓塞的唯一危险因素(P<0.001)。

核心结论

  • 即使在重症SAH且ICU治疗时间较长的高危神经重症患者中,低剂量普通肝素预防静脉血栓栓塞与治疗剂量同样有效,且出血并发症风险更低。

研究设计与样本

  • 回顾性分析重症aSAH(Fisher 3-4级)患者,在完全手术/血管内闭塞动脉瘤后ICU治疗期间接受低剂量(aPTT<40秒)或治疗范围(aPTT 50-60秒)普通肝素,共410例,平均年龄54.7±12.6岁,男女比1:2.2,aSAH相关脑出血占33.2%。

主要发现

  • 完全闭塞动脉瘤后,112例(27.3%)接受治疗剂量普通肝素,298例(72.7%)接受低剂量普通肝素。
  • 静脉血栓栓塞事件在低剂量普通肝素队列中发生率为5.4%,在治疗剂量普通肝素队列中为6.3%,两组静脉血栓栓塞事件发生率和严重程度无显著差异。
  • 治疗剂量队列中初始SAH相关脑出血增加显著更频繁(18.8% vs 3.4%,P=0.007)。
  • 肝素诱导的血小板减少症是静脉血栓栓塞的唯一危险因素(P<0.001)。
  • 普通肝素给药期间aPTT≥50秒(P=0.007)和初始存在SAH相关脑出血(P=0.035)均为颅内出血并发症的显著危险因素。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: While prophylaxis with intravenous unfractionated heparin (UFH) can effectively prevent venous thromboembolism (VTE) during the neurocritical care of patients with severe aneurysmal subarachnoid hemorrhage (aSAH), the risk for intracranial bleeding complications might increase. Owing to this therapeutic dilemma, the UFH administration regimen in this critical patient population remains highly controversial. METHODS: We performed a retrospective analysis of patients with severe aSAH (Fisher grade 3-4) receiving either low-dose (activated partial thromboplastin time [aPTT] <40 seconds) or therapeutic range (aPTT 50-60 seconds) UFH during intensive care unit (ICU) treatment after complete surgical/endovascular aneurysm occlusion. The primary outcome was the rate of bleeding/VTE complications and the investigation of potential risk factors. RESULTS: This study series comprised 410 patients with aneurysmal SAH (aSAH), with a mean age of 54.7 ± 12.6 years, a male:female ratio of 1:2.2, and aSAH-associated intracerebral hemorrhage (ICH) in 33.2%. After complete aneurysm occlusion, 112 patients (27.3%) received therapeutic dose UFH and 298 patients (72.7%) received low-dose UFH. VTE events occurred in 5.4% of the low-dose UFH cohort and in 6.3% of the therapeutic dose UFH cohort, with no significant differences in the rate and severity of VTE events. However, an increase in initial SAH-associated ICH was significantly (P = 0.007) more frequent in the therapeutic dose cohort (18.8% vs. 3.4%). Heparin-induced thrombocytopenia (HIT) was the sole risk factor for VTE (P < 0.001), and both an aPTT ≥50 seconds under UFH administration (P = 0.007) and the initial presence of SAH-associated ICH (P = 0.035) were significant risk factors for intracranial bleeding complications. CONCLUSIONS: Even in high-risk neurocritical patients with severe SAH and prolonged ICU treatment, low-dose UFH-administration for VTE prophylaxis is equally effective as therapeutic UFH administration and carries a lower risk of bleeding complications.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Kunz M, Siller S, Nell C, et al. Low-Dose versus Therapeutic Range Intravenous Unfractionated Heparin Prophylaxis in the Treatment of Patients with Severe Aneurysmal Subarachnoid Hemorrhage After Aneurysm Occlusion. World Neurosurg. 2018. PMID: 29959066. doi:10.1016/j.wneu.2018.06.118

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。